Remove Biosimilars Remove Independent Pharmacies Remove Labelling
article thumbnail

Independent Pharmacy Innovation Spotlighted at McKesson ideaShare 2025

Pharmacy Times

McKesson ideaShare 2025 brought thousands of independent pharmacists, pharmacy owners, technicians, and industry leaders together in Nashville, Tennessee, shining a spotlight on innovation and advocacy in community pharmacy.

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

CMS should draw on lessons from previous transitions, including biosimilar coverage rollouts and site-of-care policy shifts, to avoid known implementation pitfalls. This step would ensure that real-world considerations, such as off-label uses and quality-of-life impacts, are factored into revised pricing decisions. McLoughlin et al.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). million individuals in the United States aged 65 and older.

article thumbnail

FTC Issues Interim Report on Ongoing Study of Pharmacy Benefit Managers

Big Molecule Watch

The FTC asserts that “PBMs exert substantial influence over independent pharmacies” and “oversee critical decisions about access to and affordability of medications without transparency or accountability to the public.” Humana Pharmacy Solutions, Inc.; pharmacies in 2023, demonstrating this horizontal consolidation.